{"id":30806,"date":"2014-09-10T08:45:43","date_gmt":"2014-09-10T12:45:43","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=30806"},"modified":"2014-09-10T08:45:43","modified_gmt":"2014-09-10T12:45:43","slug":"united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806","title":{"rendered":"United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/10\/2014 (wallstreetpr) \u2013 <strong>Pluristem Therapeutics Inc. (NASDAQ:PSTI)<\/strong> <a href=\"http:\/\/www.marketwatch.com\/story\/united-therapeutics-advances-to-second-cohort-in-phase-i-trial-of-pluristems-plx-pad-cells-for-treatment-of-pulmonary-arterial-hypertension-2014-09-08\" target=\"_blank\">announced<\/a> that <strong>United Therapeutics Corporation (NASDAQ:UTHR)<\/strong> has successfully finished the dosing in its first group of patients covered under the Phase I study. The study used Pluristem&#8217;s PLacental eXpanded cells in patients suffering from pulmonary arterial hypertension. Now, United Therapeutics can start with the second Cohort lined up in Phase I Trial of PLX-PAD Cells. It is an important achievement for United Therapeutics as well as Pluristem as PAH has got a global market of approximately $3 billion.<\/p>\n<p style=\"text-align: justify;\"><strong>The study\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/strong><\/p>\n<p style=\"text-align: justify;\">The Phase I study is an open-label and dose-escalation study conducted in Australia. The study enrolled nine patients suffering from pulmonary arterial hypertension. The first group comprised of three patients who were given 0.5 million PLX cells per kg body weight. Now, United Therapeutics Corporation (NASDAQ:UTHR) will start with the second cohort who will be given 1 million cells per kg, and the third group of patients will be administered with 2 million cells per kilogram.<\/p>\n<p style=\"text-align: justify;\"><strong>Endpoints of the study<\/strong><\/p>\n<p style=\"text-align: justify;\">The study should result in the safety of PLX-PAD cells. It will be the primary endpoint. The result will be evaluated two times, at 12 weeks and after one year of dosing. Efficacy endpoints will be measured after six weeks of the post-treatment. It will assess the changes in respect to disease severity, cardio-respiratory function and ability to exercise. It will also measure six-minute walk distance. The evaluation of cardio-pulmonary hemodynamic parameters will be done through right heart catheterization and echocardiogram.<\/p>\n<p style=\"text-align: justify;\"><strong>The expectations<\/strong><\/p>\n<p style=\"text-align: justify;\">Zami Aberman, CEO of Pluristem Therapeutics Inc. (NASDAQ:PSTI), said that the preliminary results for the trial will be available in 2015. It will be disclosed after the dosing is completed in all three cohorts. It is an important study in development of PAH program done in association with United Therapeutics Corporation (NASDAQ:UTHR). The study is a part of 2011 licensing agreement signed between United Therapeutics and Pluristem.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/10\/2014 (wallstreetpr) \u2013 Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced that United Therapeutics Corporation (NASDAQ:UTHR) has successfully finished the dosing in its first group of [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":30810,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[2479,8579,8916,2478,8578,8577,8917],"stock_ticker":[],"class_list":["post-30806","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqpsti","tag-nasdaquthr","tag-pluristem-therapeutics-inc","tag-pluristem-therapeutics-inc-nasdaqpsti","tag-united-therapeutics-corporation","tag-united-therapeutics-corporation-nasdaquthr","tag-zami-aberman","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/10\/2014 (wallstreetpr) \u2013 Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced that United Therapeutics Corporation (NASDAQ:UTHR) has successfully finished the dosing in its first group of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-10T12:45:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/UNI.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"150\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients\",\"datePublished\":\"2014-09-10T12:45:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806\"},\"wordCount\":327,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/UNI.jpg\",\"keywords\":[\"NASDAQ:PSTI\",\"NASDAQ:UTHR\",\"Pluristem Therapeutics Inc.\",\"Pluristem Therapeutics Inc. (NASDAQ:PSTI)\",\"United Therapeutics Corporation\",\"United Therapeutics Corporation (NASDAQ:UTHR)\",\"Zami Aberman\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806\",\"name\":\"United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/UNI.jpg\",\"datePublished\":\"2014-09-10T12:45:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/UNI.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/UNI.jpg\",\"width\":300,\"height\":150},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806","og_locale":"en_US","og_type":"article","og_title":"United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients - Wall Street PR","og_description":"Boston, MA 09\/10\/2014 (wallstreetpr) \u2013 Pluristem Therapeutics Inc. (NASDAQ:PSTI) announced that United Therapeutics Corporation (NASDAQ:UTHR) has successfully finished the dosing in its first group of [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-10T12:45:43+00:00","og_image":[{"width":300,"height":150,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/UNI.jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients","datePublished":"2014-09-10T12:45:43+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806"},"wordCount":327,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/UNI.jpg","keywords":["NASDAQ:PSTI","NASDAQ:UTHR","Pluristem Therapeutics Inc.","Pluristem Therapeutics Inc. (NASDAQ:PSTI)","United Therapeutics Corporation","United Therapeutics Corporation (NASDAQ:UTHR)","Zami Aberman"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806","url":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806","name":"United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/UNI.jpg","datePublished":"2014-09-10T12:45:43+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/UNI.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/UNI.jpg","width":300,"height":150},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/united-therapeutics-corporation-nasdaquthr-completes-dosing-of-first-group-of-patients-30806#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"United Therapeutics Corporation (NASDAQ:UTHR) Completes Dosing Of First Group Of Patients"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/30806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=30806"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/30806\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/30810"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=30806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=30806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=30806"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=30806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}